

REMARKS/ARGUMENTS

The title of the application has been amended to "MCP-1 Receptor Antibodies" in light of the claims. Support for this amendment can be found in the claims and on page 23, paragraph [0086], line 30. No new matter was added by this amendment.


Applicants request entry of the *Sequence Listing* in adherence with 37 C.F.R. § 1.821 - 1.825. This preliminary amendment is accompanied by a paper copy of the *Sequence Listing* which has been printed from the computer readable disk. The information contained in the computer readable disk was prepared through the use of the software program "PatentIn 3.0" and is identical to that of the paper copy. The computer readable form in the instant application is identical to the *Sequence Listing* filed in Application No. 09/625,573, filed July 25, 2000 and Application No. 08/446,669, filed May 25, 1995, now U.S. Patent 6,132,987. In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed in Application No. 08/446,669 (now U.S. Patent 6,132,987) as the computer readable form for the instant application. No new matter was added by this amendment.

It is understood that the Patent and Trademark Office will make the necessary changes in the application number, filing date, correspondence address, and attorney/agent information of the computer readable form that will be used for the instant application. A paper copy of the *Sequence Listing* is included herewith.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Brigitte A. Hajos
Reg. No. 50,971

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 415-576-0300
60150294 v1